Kafocin is developed by Eli Lilly.

What development phase is Kafocin in?

Kafocin is FDA-approved (marketed).

What is the generic name of Kafocin?

cefaloglycin is the generic (nonproprietary) name of Kafocin.

Last reviewed 2026-04-20 · How we verify

Kafocin (cefaloglycin)

Eli Lilly · FDA-approved active Quality 14/100

Cefaloglycin (Kafocin), marketed by Eli Lilly, is a bacterial cell wall synthesis inhibitor positioned in the antibiotic market with a key composition patent expiring in 2028. Its primary competitive advantage lies in its distinct mechanism of action and patent protection, which differentiates it from off-patent competitors like ampicillin and benzylpenicillin. The primary risk to Kafocin's market position is the presence of multiple generic same-target drugs, such as amoxicillin and bacampicillin, which may erode its market share.

At a glance

Generic name	cefaloglycin
Sponsor	Eli Lilly
Drug class	cefaloglycin
Target	Bacterial penicillin-binding protein
Therapeutic area	Metabolic
Phase	FDA-approved
First approval	1970

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Kafocin CI brief — competitive landscape report
Kafocin updates RSS · CI watch RSS
Eli Lilly portfolio CI